Cullinan Therapeutics, Inc.
CGEM- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001789972
In the last 90 days, Cullinan Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 183 institutions reported holding it in 13F filings for Q2 2026, worth $1.30B in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Cullinan Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 71 | 66 | −5 |
| Shares | 32.3M | 33.9M | +1.61M (+5.0%) |
| Value | $828.5M | $762.3M | −$66.3M (−8.0%) |
New holders (7)
Institutions that held Cullinan Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Schonfeld Strategic Advisors LLC | 35,858 | $809.0K | 0.01% |
| Mirabella Financial Services LLP | 29,686 | $670.0K | 0.09% |
| SG Americas Securities, LLC | 15,863 | $358.0K | 0.00% |
| Bailard, Inc. | 9,600 | $217.0K | 0.01% |
| Voya Investment Management LLC | 9,518 | $215.0K | 0.00% |
| Invesco Ltd. | 9,127 | $205.0K | 0.00% |
| US Bancorp | 10 | $0 | 0.00% |
Sold out (12)
Institutions that held Cullinan Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Ikarian Capital, LLC | 295,596 | $7.61M |
| Eversept Partners, LP | 163,880 | $4.22M |
| Adage Capital Partners GP, L.L.C. | 78,000 | $2.01M |
| Silverarc Capital Management, LLC | 75,732 | $1.95M |
| Marshall Wace, LLP | 74,951 | $1.93M |
| D. E. Shaw & Co., Inc. | 60,319 | $1.55M |
| Affinity Asset Advisors, LLC | 45,000 | $1.16M |
| Boothbay Fund Management, LLC | 39,113 | $1.01M |
| Renaissance Technologies LLC | 25,982 | $669.0K |
| O'Shaughnessy Asset Management, LLC | 2,912 | $75.0K |
| Lazard Asset Management LLC | 2,273 | $58.0K |
| Signaturefd, LLC | 29 | $1.00K |